In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 136 for your search:

Drug:  cyclosporine
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Phase: Phase IV
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: SMD/ATG-CSA/2002, NCT00488436

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-Based Immunosuppressive Protocol

Phase: Phase IV
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PROSKIN 01, NCT00866684

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Under 30
Sponsor: NCI, Other
Protocol IDs: AHOD0121, CDR0000330135, COG-AHOD0121, NCT00070187

Stem Cell Transplant for Bone Marrow Failure Syndromes

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 35 and under
Sponsor: Other
Protocol IDs: MT2000-18, 9504M09637, NCT00176878

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 55 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000066016, P30CA016059, MCV-CCHR-9504-2X, DUMC-75951, NCI-G98-1388, NCT00003187

Phase III Randomized Study of ARA-C/DNR with vs without CYSP in Patients with CML in Blast Phase (Summary Last Modified 04/98)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: SWOG-9032

Phase III Nonrandomized Study of Allogeneic Bone Marrow Transplantation Following First Remission for Children with High-Risk Acute Lymphoblastic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 6 months to 21 years
Sponsor: NCI
Protocol IDs: CCG-1921

Phase III Randomized Study of ARA-C/DNR with vs without the Drug Resistance Inhibitor CYSP in High-Risk Patients with AML

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: SWOG-9126

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000258113, U10CA021115, E1900, ECOG-1900, NCT00049517

10.

Total-Body Irradiation With Or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1813.00, NCI-2009-01532, P01CA078902, FHCRC-1813.00, 5666, NCT00075478

11.

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2003.333, NCT00133887

12.

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 1992.00, NCI-2010-00737, P01CA078902, K23HL084054, P01CA018029, P01HL036444, FHCRC-1992.00, 6170, NHLBI-K23-HL084054-01A1, NCT00322101

13.

Phase III Study of Induction and Maintenance Therapy Comprising Etoposide, Dexamethasone, and Cyclosporine Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Inherited or Severe and Persistent Secondary Hemophagocytic Lymphohistiocytosis. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Under 18
Sponsor: Other
Protocol IDs: CCLG-LCH-2006-02, EU-20619, UKCCSG-HLH-2004, EUDRACT-2005-002187-28, NCT00334672

14.

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 30
Sponsor: NCI, Other
Protocol IDs: AAML0531, COG-AAML0531, CDR0000487497, NCT00372593

15.

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 22
Sponsor: NCI, Other
Protocol IDs: CDR0000532926, COG-ASCT0631, COG-PBMTC-STC051, ASCT0631, NCT00450450

16.

Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 12 to 65
Sponsor: Other
Protocol IDs: PROGAST, NCT00180089

17.

Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: 467, 2U01HL069294, BMTCTN-0501, FHCRC-2128.00, NCT00412360

18.

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia

Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI, Other
Protocol IDs: 1092.00, FHCRC-1092.00, NCI-H96-0926, CDR0000064853, NCT00002789

19.

Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 72
Sponsor: NCI, Other
Protocol IDs: 09-073, NCT00928018

20.

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 to 55
Sponsor: NCI, Other
Protocol IDs: CDR0000067898, S9920, U10CA032102, SWOG-S9920, NCT00005866

21.

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 267.01, FHCRC-267.01, FHCRC-267.00, NCI-V86-0145, CDR0000074146, NCT00002456

22.

Phase I/II Trial of CY and Hyperfractionated TBI as Conditioning for Allogeneic Bone Marrow Transplantation in Patients with Advanced ALL and Malignant Lymphoma (Summary Last Modified 02/89)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 50 and under
Sponsor:
Protocol IDs: FHCRC-408, NCI-V88-0474

23.

Phase I/II Pilot Study of CYSP/IFN-G-Induced Graft-Versus-Host Effect in Patients with Small Cell Lung Cancer Who Undergo Autologous Bone Marrow Transplantation Following Conventional Induction Chemotherapy and High-Dose Chemoradioablation

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 15 to 60
Sponsor: Other
Protocol IDs: TUHSC-2110, NCI-V92-0200

24.

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000370797, CALGB-100102, NCT00085449

25.

Phase I/II Pilot Study of Induction Therapy Comprising Fludarabine and Cyclophosphamide Followed By Allogeneic Stem Cell Transplantation in Patients With High-Risk B-Cell Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL3X, EU-20554, MEDAC-FLUD.10/CLL, NCT00281983

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map